Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · NRX Pharmaceuticals, Inc. (NRXP)

NRx Pharmaceuticals wins FDA approval for preservative-free ketamine ahead of goal date

Positive Impact 3 of 5 legal/regulatory Written later

NRx Pharmaceuticals said the FDA approved its Abbreviated New Drug Application for Preservative-Free Ketamine ahead of the November 10, 2026 GDUFA goal date. The company says it now has commercial supply on hand to label the product and sell it to American hospitals and clinics, but the filing gives no sales, revenue or earnings figures.

Key points

  • FDA approved the company's ANDA for Preservative-Free Ketamine, announced October 30, 2026, ahead of the November 10, 2026 goal date.
  • The company says the product contains no benzethonium chloride, a preservative it describes as not GRAS-designated by the FDA.
  • Manufacturing is with Nephron Pharmaceuticals in West Columbia, South Carolina.
  • The company says it can now label the product and supply American hospitals and clinics.

The filing

CompanyNRX Pharmaceuticals, Inc. (NRXP)
Form8-K, current report
Filed with the SECNov 2, 2026, 8:06 AM ET
Accession number0001437749-26-034284

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.